Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC
Conditions
- Non Small Cell Lung Cancer
Interventions
- DRUG: Nivolumab
- DIAGNOSTIC_TEST: 3D-EX
- OTHER: Evaluation of Response by RECIST
Sponsor
Nilogen Oncosystems
Collaborators